Hepatocellular carcinoma treated with transarterial chemoembolization in cirrhotic and non-cirrhotic liver retrospective analysis

ROHAN, Tomáš, Michal UHER, Peter MATKULČÍK, Jan ZAVADIL, Vlastimil VÁLEK and Tomáš ANDRAŠINA. Hepatocellular carcinoma treated with transarterial chemoembolization in cirrhotic and non-cirrhotic liver retrospective analysis. In ECIO 2020. 2020.

Basic information

• Original name: Hepatocellular carcinoma treated with transarterial chemoembolization in cirrhotic and non-cirrhotic liver retrospective analysis
• Authors: ROHAN, Tomáš (203 Czech Republic, guarantor, belonging to the institution), Michal UHER (203 Czech Republic, belonging to the institution), Peter MATKULČÍK (703 Slovakia, belonging to the institution), Jan ZAVADIL (203 Czech Republic, belonging to the institution), Vlastimil VÁLEK (203 Czech Republic, belonging to the institution) and Tomáš ANDRAŠINA (703 Slovakia, belonging to the institution).
• Edition: ECIO 2020, 2020.

Other information

• Original language: English
• Type of outcome: Presentations at conferences
• Field of Study: 30224 Radiology, nuclear medicine and medical imaging
• Country of publisher: France
• Confidentiality degree: is not subject to a state or trade secret
• WWW: URL
• RIV identification code: RIV/00216224:14110/20:00116825
• Organization unit: Faculty of Medicine
• Keywords in English: hepatocellular carcinoma; transarterial chemoembolization; survival analysis
• Tags: rivok
• Tags: International impact

Abstract

Purpose To compare results of hepatocellular carcinoma treatment with transarterial chemoembolization and identify prognostic factors affecting survival. Material and methods Retrospective analysis of patients with HCC treated with TACE in tertially referal hospital in 2005-2018. Based on the presence of the chronic liver disease were patient divided in two groups (with and without chronic liver disease). In each group were on CT/MRI before initial TACE evaluated and statistically analysed (survival log rank test, uni and multivariate analysis) dedicated prognostic factors (one or more lesion, size of the biggest lesion, uni or bilobar disease, portal vein trombosis). Results In the analysis were included 122 patients (18% females, avg 66 years) with known chronic liver disease and 35 patients (16.7% females, avg. 66 years) without known liver disease. Although the biggest lesion was significantly bigger in patients without chronic liver disease (median 11.0 vs 6.0 cm, p=0,001), the survival rate from 1.TACE was higher in this group (median 35.3 vs 20.0 months, p=0,078), any other evaluated risk factors except the presence of chronic liver disease were significantly different. The most important survival risk factor except the chronic liver disease was in both groups the size of the lesion (HR 1.264/cm vs 1.125/cm) and bilobar involvement (HR 5.576 vs 2.257), in addition, in chronic liver disease also portal vein thrombosis (HR 3.279). Conclusion Better survival rate was observed in HCC in liver without chronic disease, although the lesions were significantly larger. The most important risk factor in this group was bilobar involvement and the size of the biggest lesion.

Links

• MUNI/A/1488/2019, interní kód MU: Name: Význam radiologických intervencí a pokročilých zobrazovacích metod v diagnostice a léčbě onkologických pacientů

Investor: Masaryk University, Category A